9AVQ
Crystal structure of SARS-CoV-2 main protease A191T mutant in complex with an inhibitor Nirmatrelvir
Summary for 9AVQ
| Entry DOI | 10.2210/pdb9avq/pdb |
| Descriptor | 3C-like proteinase nsp5, (1R,2S,5S)-N-{(1E,2S)-1-imino-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-6,6-dimethyl-3-[3-methyl-N-(trifluoroacetyl)-L-valyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide, DI(HYDROXYETHYL)ETHER, ... (4 entities in total) |
| Functional Keywords | sars-cov-2 main protease, 3c-like proteinase, viral protein, sars-cov-2, hydrolase-inhibitor complex, hydrolase/inhibitor |
| Biological source | Severe acute respiratory syndrome coronavirus 2 (2019-nCoV, SARS-CoV-2) |
| Total number of polymer chains | 1 |
| Total formula weight | 34463.23 |
| Authors | Bulut, H.,Hattori, S.,Hayashi, H.,Hasegawa, K.,Li, M.,Wlodawer, A.,Tamamura, H.,Mitsuya, H. (deposition date: 2024-03-04, release date: 2024-04-24, Last modification date: 2024-11-13) |
| Primary citation | Hattori, S.I.,Bulut, H.,Hayashi, H.,Kishimoto, N.,Takamune, N.,Hasegawa, K.,Furusawa, Y.,Yamayoshi, S.,Murayama, K.,Tamamura, H.,Li, M.,Wlodawer, A.,Kawaoka, Y.,Misumi, S.,Mitsuya, H. Structural and virologic mechanism of the emergence of resistance to M pro inhibitors in SARS-CoV-2. Proc.Natl.Acad.Sci.USA, 121:e2404175121-e2404175121, 2024 Cited by PubMed Abstract: We generated SARS-CoV-2 variants resistant to three SARS-CoV-2 main protease (M) inhibitors (nirmatrelvir, TKB245, and 5h), by propagating the ancestral SARS-CoV-2 in VeroE6 cells with increasing concentrations of each inhibitor and examined their structural and virologic profiles. A predominant E166V-carrying variant (SARS-CoV-2), which emerged when passaged with nirmatrelvir and TKB245, proved to be resistant to the two inhibitors. A recombinant SARS-CoV-2 was resistant to nirmatrelvir and TKB245, but sensitive to 5h. X-ray structural study showed that the dimerization of M was severely hindered by E166V substitution due to the disruption of the presumed dimerization-initiating Ser1'-Glu166 interactions. TKB245 stayed bound to M, whereas nirmatrelvir failed. Native mass spectrometry confirmed that nirmatrelvir and TKB245 promoted the dimerization of M, and compromised the enzymatic activity; the Ki values of recombinant M for nirmatrelvir and TKB245 were 117±3 and 17.1±1.9 µM, respectively, indicating that TKB245 has a greater (by a factor of 6.8) binding affinity to M than nirmatrelvir. SARS-CoV-2 selected with 5h acquired A191T substitution in M (SARS-CoV-2) and better replicated in the presence of 5h, than SARS-CoV-2. However, no significant enzymatic or structural changes in M were observed. The replicability of SARS-CoV-2 proved to be compromised compared to SARS-CoV-2 but predominated over SARS-CoV-2 in the presence of nirmatrelvir. The replicability of SARS-CoV-2 surpassed that of SARS-CoV-2 in the absence of 5h, confirming that A191T confers enhanced viral fitness. The present data should shed light on the understanding of the mechanism of SARS-CoV-2's drug resistance acquisition and the development of resistance-repellant COVID-19 therapeutics. PubMed: 39236245DOI: 10.1073/pnas.2404175121 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (2.58 Å) |
Structure validation
Download full validation report
